Medical Treatment for Hepatocellular Carcinoma in Japan

Youichi Kawano; Yohei Kaneya; Yuto Aoki; Masato Yoshioka; Akira Matsushita; Tetsuya Shimizu; Junji Ueda; Hideyuki Takata; Nobuhiko Taniai; Tomohiro Kanda; Atsushi Hirakata; Hideyuki Suzuki; Hiroshi Yoshida

doi:10.1272/jnms.JNMS.2022_89-224

Reviews

Medical Treatment for Hepatocellular Carcinoma in Japan

Youichi Kawano, Yohei Kaneya, Yuto Aoki, Masato Yoshioka, Akira Matsushita, Tetsuya Shimizu, Junji Ueda, Hideyuki Takata, Nobuhiko Taniai, Tomohiro Kanda, Atsushi Hirakata, Hideyuki Suzuki, Hiroshi Yoshida

Author information

JOURNAL FREE ACCESS

2022 Volume 89 Issue 2 Pages 154-160

DOI https://doi.org/10.1272/jnms.JNMS.2022_89-224

Browse “Advance online publication” version

Details

Abstract

Liver cancer, including hepatocellular carcinoma (HCC), is the fifth most common cause of cancer deaths in Japan. The main treatment options for HCC are surgical resection, liver transplantation, radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and systemic chemotherapy. Here, recent medical treatments for HCC, including surgery, percutaneous ablation, transcatheter arterial chemoembolization/transcatheter arterial embolization, and drug therapy, are reviewed with a focus on Japan.

Corresponding author

Register with J-STAGE for free!